Galmed Pharmaceuticals
GLMD
29 hedge funds and large institutions have $61.1M invested in Galmed Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 11 closing their positions.
17% more capital invested
Capital invested by funds: $52.2M → $61.1M (+$8.86M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.03% → 0.02% (-0%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
22% less funds holding
Funds holding: 37 → 29 (-8)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $111K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$1.29M |
| 2 |
JP Morgan Chase
New York
|
+$291K |
| 3 |
DG
Delek Group
Herzliya,
Israel
|
+$174K |
| 4 |
Goldman Sachs
New York
|
+$140K |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$507K |
| 2 |
PAM
Premier Asset Management
Chicago,
Illinois
|
-$505K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$361K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$314K |
| 5 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$291K |
GLMD Hedge Fund Activity: Q1 2019 in Review
29 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2019, worth a combined $61.1M — up 17% from $52.2M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GLMD and 3 opened new positions — a net loss of 8 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Ibex Investors, adding an estimated $1.29M. The largest seller was Spark Investment Management, exiting entirely with an estimated $507K sold.
- 29 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2019, down from 37 in Q4 2018.
- Funds reported $61.1M of Galmed Pharmaceuticals stock for Q1 2019, up 17% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q1 2019 and 11 closed out, a net change of -8 holders.
- The largest Galmed Pharmaceuticals buyer in Q1 2019 was Ibex Investors, an estimated $1.29M added.
- The largest Galmed Pharmaceuticals seller in Q1 2019 was Spark Investment Management, an estimated $507K sold.
Based on aggregated 13F filings for Q1 2019.